Redeye: Vitrolife - The tough get going
22 juli, 08:29
22 juli, 08:29
Vitrolife faces a tough H2 in 2025, and we expect this to continue during H1 2025. In short, Vitrolife is stepping up its investments in commercial capacity and sales during a period of softer organic growth. In Q2, the softer areas are the APAC regions and technologies, apart from pressure in FX (-8%) and discontinued EMEA business.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
22 juli, 08:29
Vitrolife faces a tough H2 in 2025, and we expect this to continue during H1 2025. In short, Vitrolife is stepping up its investments in commercial capacity and sales during a period of softer organic growth. In Q2, the softer areas are the APAC regions and technologies, apart from pressure in FX (-8%) and discontinued EMEA business.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
ECB
Analyser
Rapportperioden
Kryptovalutor
ECB
Analyser
Rapportperioden
Kryptovalutor
1 DAG %
Senast
Börsen idag
Igår, 17:47
Positivt på Stockholmsbörsen – Astra Zeneca lyfter efter positiva studieresultat
Integrum
Igår, 14:50
Budet på Integrum: Rekordhög premie
OMX Stockholm 30
1 DAG %
Senast
2 600,22